Hemostemix Inc. (CVE:HEM – Get Free Report) traded up 7.3% during mid-day trading on Wednesday . The company traded as high as C$0.30 and last traded at C$0.30. 107,500 shares traded hands during mid-day trading, a decline of 84% from the average session volume of 657,849 shares. The stock had previously closed at C$0.28.
Hemostemix Price Performance
The firm has a market capitalization of C$24.83 million, a price-to-earnings ratio of -14.25 and a beta of 0.20. The firm’s fifty day moving average is C$0.11 and its 200 day moving average is C$0.08.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Recommended Stories
- Five stocks we like better than Hemostemix
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Oracle Announces Game-Changing News for the AI Industry
- What Are Dividend Challengers?
- Netflix Adds 19 Million Subscribers, Growth Is Far For Over
- Insider Trades May Not Tell You What You Think
- Tempus AI: A Game-Changer in AI-Powered Healthcare
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
